EU Launches Joint Assessment Of Pediatric & Orphan Drugs Legislation

A new European Commission consultation marks the launch of an evaluation exercise to assess the joint impact of the EU pediatric and orphan drugs legislation in supporting the development of pediatric medicines for rare diseases.

ChildHandWithIV_1200x675
Joint Evaluation Will Look At Effectiveness Of EU Rules On Pediatric And Orphan Drugs • Source: Shutterstock

The European Commission has finally launched its much-awaited joint evaluation of the EU pediatric and orphan drugs legislation as part of ongoing efforts to assess why the combined effects of these legal instruments have failed to deliver major therapeutic advances in diseases that are rare and/or unique in children.

Stakeholders have until Jan. 4, 2019 to respond to an online questionnaire concerning medicines for pediatric diseases that qualify...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography